Drug repurposing and repositioning in the market is an accepted strategy to market, but that people are saying this is a failed strategy? I thought this was the whole point of nadolol. Low dose to air-borne delivery. The feasability and toxicology on inhaled was started. The data on low dose was promising. At any rate, what has changed, other than a lack of a deal. BTW I understand the frustration.
Wrong commercial strategy?, page-18
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(33.3%) |
Mkt cap ! $17.04M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.3¢ | 0.2¢ | $10.78K | 5.327M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 115290 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 12982483 | 52 |
View Market Depth
| Last trade - 14.55pm 19/11/2024 (20 minute delay) ? |
| IVX (ASX) Chart |